AMPH

Lilly to Divest BAQSIMI to Amphastar

Retrieved on: 
Monday, April 24, 2023
CIBC Bank USA, AMPH, P.C, Insulin, JPMorgan Chase, Covington & Burling, Gland, Diabetes, Kirkland & Ellis, Marketing, Neoplasm, Cathay Bank, Glucagon, Pancreas, Wilson Sonsini Goodrich & Rosati, GAAP, Obesity, Wilson, Capital One, Eli Lilly, Wells Fargo, LLY, Jefferies Group, Hypoglycemia, Acquisition, Allergy, Patient, Insulinoma, Pheochromocytoma, J. P. Morgan, Growth, NYSE, Fifth Third Bank, Eli Lilly and Company, Pharmaceutical industry, Bank, Amphastar Pharmaceuticals, Lilly

INDIANAPOLIS and RANCHO CUCAMONGA, Calif., April 24, 2023 /PRNewswire/ -- In an effort to continue expanding the availability of BAQSIMI® to patients, Eli Lilly and Company (NYSE: LLY) and Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) have entered into a definitive agreement for Lilly to divest BAQSIMI worldwide to Amphastar, a global pharmaceutical company focused on developing, manufacturing, and marketing injectable, intranasal, and inhalation products including experience with a glucagon product. BAQSIMI is the first and only nasally administered glucagon for the treatment of severe hypoglycemia in people with diabetes.

Key Points: 
  • INDIANAPOLIS and RANCHO CUCAMONGA, Calif., April 24, 2023 /PRNewswire/ -- In an effort to continue expanding the availability of BAQSIMI® to patients, Eli Lilly and Company (NYSE: LLY) and Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) have entered into a definitive agreement for Lilly to divest BAQSIMI worldwide to Amphastar, a global pharmaceutical company focused on developing, manufacturing, and marketing injectable, intranasal, and inhalation products including experience with a glucagon product.
  • Amphastar expects to provide dedicated commercial investment for BAQSIMI with the goal of enabling more people on insulin to be prepared with a glucagon rescue treatment for severe hypoglycemia.
  • Lilly launched BAQSIMI in 2019 as an option to quickly render aid in rescue situations for people with diabetes who take insulin and it is currently available in 27 international markets.
  • Each of Lilly and Amphastar will determine their applicable accounting treatment for this transaction according to Generally Accepted Accounting Principles (GAAP) upon closing.

EQS-News: Can This Company’s Positive Results For Psychedelic Combination Treatment Provide Hope For Alcohol And Cocaine Addiction Problems?

Retrieved on: 
Sunday, November 27, 2022
California Rehabilitation Center, Growth, Heart, Spleen, United Nations Office on Drugs and Crime, THC, WHO, Drug overdose, Tourette syndrome, Hand, Agitation, SUD, Pain, Safety, Brain, Advertising, Chronic pain, Research report, United Nations, PEA, Cocaine, Autism, World Drug Report, National Center for Telehealth & Technology, Rat, Pancreas, Inflammation, Death, Addiction, AMPH, World Health Organization, CNS, Disease, UNODC, Status epilepticus, Crave, CBD, Alzheimer's disease, Disability-adjusted life year, Drug, Research, Therapy, Thyroid, Viatris, CSE, Substance abuse, Animal, Liver, Probability, MEAI, Pharmaceutical industry, Crime

Can This Companys Positive Results For Psychedelic Combination Treatment Provide Hope For Alcohol And Cocaine Addiction Problems?

Key Points: 
  • Can This Companys Positive Results For Psychedelic Combination Treatment Provide Hope For Alcohol And Cocaine Addiction Problems?
  • Whether its a problem with opioids, alcohol, cocaine, or even using pain meds, an unchecked addiction can be fatal.
  • Take alcohol abuse, for example; the World Health Organization (WHO) estimates that three million deaths yearly result from the harmful use of alcohol.
  • On Aug. 24, the company announced additional positive preclinical results of its psychedelic-based pharma collaboration for treating cocaine addiction using MEAI.